CClinicalTrials.gg
RecruitingNCT04872517Updated Sep 7, 2023

Meridian Energy Changes of Head and Neck Cancer Patients After Chemotherapy or Radiotherapy

An interventional study of Meridian Electroacupuncture Analysis Device (MEAD) in Head and Neck Cancer, sponsored by Liao Jian An. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Liao Jian An · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This trial is conducted by using MEAD to detect the meridian changes in patients with head and neck cancer after conventional treatment of chemotherapy or radiotherapy.

Read the detailed description

The purpose of this research is observe the change of meridian energy in patients have be diagnosed with head and neck cancer. The instrument we use is a non-invasive device called meridian energy analysis device(MEAD). The theory of MEAD is use conductive rod to measure the skin resistance from the specific point in human body, and to calculate the meridian's energy change. In Traditional Chinese Medicine theory, physician doctor believe that the median in human body would be affected by disease or uncomfortable condition. So, this time, we who a group of physician of Traditional Chinese medicine department conduct this research to assess the energy change in patients with head and neck cancer. The trail cooperate with radiation oncology department and hematology oncology department. Subject enrollment from radiation oncology department and hematology Oncology department. All of subjects have be diagnosed with head and neck cancer, and will to receive conventional treatment, no matter chemotherapy or/and radiotherapy.

The major assessment of our research is meridian energy by MEAD before treatment, and six consecutive cycles. In addition to this, pain degree, oral mucositis condition, impact on life quality, and blood test, diagnosis imaging data will be collected.

According to G*Power( 3.1.9.4 edition), we expected to recruit 34 subjects. All of Statistical Analysis will use SPSS, pair-t test is used to analyze continuous variable, categorical variable will be analyzed by Chi-Square Test. Multivariate regression analysis will be apply to discuss the major factor of the meridian changes.

MEAD is a kind of non-invasive device, hasn't had adverse effect until now. We will start emergency handling If accidents happened within measurement.

02

Conditions studied

  • Head and Neck Cancer
03

In context

Head and Neck Neoplasms

2,344 studies on the registry are indexed under Head and Neck Neoplasms; 551 are open to participants now.

This study's planned enrollment of 34 is below the median of 47 across 1,751 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

This is the only study on the registry with Liao Jian An as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. patients with head and neck cancer, included nasopharyngeal carcinoma, laryngeal cancer, oropharyngeal cancer, ear and oral cancer, hypopharyngeal cancer, salivary-gland carcinoma. Aged between 20 years old to 75years old, no gender difference.
  2. patients with head and neck cancer has not received surgery yet, and will plan to accept chemotherapy and/or radiotherapy.
  3. recurrent head and neck cancer, and expect to received chemotherapy and/or radiotherapy.
  4. patient with vital sings stableness, conscious clear, and have ability to recognize the contain of trail and sign consent.
  5. not accept other adjuvant therapy.
  6. no brain metastasis or psychosis, and will to join whole course as well as accept assessments.

Exclusion criteria

Exclusion Criteria:

  1. Aged less than 20 years old and over 75 years old。
  2. Patients be diagnosed with head and neck cancer, and accepted surgery, or already finished chemotherapy and/or radiotherapy.
  3. patient with brain metastasis, conscious unclear, and have not able to recognize the contain of trail and sign consent.
  4. Accept other adjuvant therapy and chemotherapy and/or radiotherapy simultaneously.
  5. Combined with serious organs failure。
  6. Have contraindication in chemotherapy or radiotherapy.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    34 head and neck cancer patients, expected to proceed chemotherapy or radiotherapy in hospital.

    Total 34 anticipants will recruit in this research. Age was limited between 20years old to 75 years old. All of anticipants agree to join this trail and be followed through treatment , and without underlying disease that threaten life.

    Device: Meridian Electroacupuncture Analysis Device (MEAD)

Interventions

  • DeviceMeridian Electroacupuncture Analysis Device (MEAD)

    use MEAD to detect energy change in patient with head and neck cancer

06

What researchers measure

Primary outcomes

  1. meridian energy

    energy change in meridian

    Time frame: An average of 6 weeks

Secondary outcomes

  1. the number of participants with blood test data abnormal

    calculate the ratio of participants in hemodynamic alteration whom accept chemotherapy or/and radiotherapy, and compare the hemodynamic change with meridian energy change. Blood test include CBC/DC (WBC, RBC, Hemoglobin, Hematocrit, platelets, segment, lymphocyte, absolutely neutrophil), GOT/GPT, Bun/Creatinine, Bilirubin.

    Time frame: An average of 6 weeks

  2. pain degree

    use Numerical Rating Scale(0-10) to assess.

    Time frame: An average of 6 weeks

  3. Oral mucositis grading

    compare enrollment subjects's oral condition with picture from MASCC/ISOO clinical practice guidelines (grade 0-grade 4)

    Time frame: An average of 6 weeks

  4. adverse impact on quality of life

    use EORTC QLQ - H\&N35 questionnaire to evaluate the treatment impact on subject feeling

    Time frame: An average of 6 weeks

  5. imaging diagnosis

    compare tumor condition in diagnostic image data (shrink or progress) with the energy change in meridian.

    Time frame: An average of 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Chang Cung Memorial Hospital
    Keelung, 20401, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04872517
Lead sponsor
Liao Jian An
Responsible party
Liao Jian An (Attending physician of Traditional Chinese Medicine department, Chang Gung Memorial Hospital) — Sponsor-investigator
First posted
May 4, 2021
Start date
Apr 1, 2021
Primary completion
Dec 31, 2023 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Sep 7, 2023

Study contacts

Chao-Hua Fang
Contact
yihwa0813@yahoo.com.tw
886-2-24313131 ext. 2501
Jian-An Liao
Contact
frank771124@hotmail.com
886-2-24313131 ext. 2501
Jian-An Liao
principal investigator · medical attending

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion